PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY
The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.
1 - 195 . (canceled)
196 . A method of prophylactically treating a subject for variceal bleeding, which comprises orally administering to the subject a somatostatin analog or a composition comprising a somatostatin analog.
197 . The method of claim 196 , wherein the somatostatin analog is octeotride.
198 . The method of claim 196 , wherein the prophylaxis is primary.
199 . The method of claim 196 , wherein the prophylaxis is secondary.
200 . The method of claim 196 , wherein the variceal bleeding is associated with portal hypertension.
201 . The method of claim 196 , wherein the varices are gastric or esophageal.
202 . The method of claim 196 , wherein the somatostatin analog is administered once daily.
203 . The method of claim 196 , wherein the somatostatin analog is administered twice or more daily.
204 . A method of treating a subject suffering from portal hypertension or variceal bleeding, comprising orally administering to the subject a somatostatin analog or a composition comprising a somatostatin analog.
205 . The method of claim 204 , wherein the somatostatin analog is octeotride.
206 . The method of claim 204 , wherein the subject suffers from variceal bleeding.
207 . The method of claim 204 , wherein the varices are gastric or esophageal.
208 . The method of claim 204 , wherein the subject suffers from portal hypertension.
209 . The method of claim 204 , wherein the therapeutic agent is administered once daily.
210 . The method of claim 204 , wherein the therapeutic agent is administered twice or more daily.
211 . A method of treating a subject suffering from abnormal GI motility, flushing episodes associated with carcinoid syndrome, an endocrine tumor (such as carcinoids, VIPoma), gastroparesis, diarrhea, pancreatic leak or a pancreatic pseudo-cyst, or hepato-renal syndrome, shock of hypovolemic (e.g. hemorrhagic) or vasodilatory (e.g. septic) origin, cardiopulmonary resuscitation or anesthesia-induced hypotension, comprising orally administering to the subject a somatostatin analog or a composition comprising a somatostatin analog.
212 . The method of claim 211 , wherein the somatostatin analog is octeotride.
213 . A method of prophylactically treating a subject for variceal bleeding, which comprises orally administering to the subject a vasopressin analog or a composition comprising a vasopressin analog.
214 . The method of claim 213 , wherein the vasopressin analog is terlipressin.
215 . The method of claim 213 , wherein the prophylaxis is primary.
216 . The method of claim 213 , wherein the prophylaxis is secondary.
217 . The method of claim 213 , wherein the variceal bleeding is associated with portal hypertension.
218 . The method of claim 213 , wherein the therapeutic agent is administered once daily.
219 . The method of claim 213 , wherein the therapeutic agent is administered twice or more daily.
220 . A method of treating a subject suffering from hepato-renal syndrome (HRS), bleeding esophageal varices or portal hypertension, which comprises orally administering to the subject a vasopressin analog or a composition comprising a vasopressin analog.
221 . The method of claim 220 , wherein the subject suffers from hepato-renal syndrome (HRS).
222 . The method of claim 220 , wherein the hepato-renal syndrome (HRS) is HRS I.
223 . The method of claim 220 , wherein the hepato-renal syndrome (HRS) is HRS II.
224 . The method of claim 220 , wherein the subject suffers from bleeding esophageal varices.
225 . The method of claim 220 , wherein the subject suffers from portal hypertension.
226 . The method of claim 220 , wherein the vasopres sin analog is terlipressin.
227 . The method of claim 220 , wherein the variceal bleeding is associated with portal hypertension.
228 . The method of claim 220 , wherein the varices are gastric or esophageal.
229 . The method of claim 220 , wherein the therapeutic agent is administered once daily.
230 . The method of claim 220 , wherein the therapeutic agent is administered twice or more daily.